Previous 10 | Next 10 |
Gainers: VivoPower International (NASDAQ: VVPR ) +52% . ENDRA Life Sciences (NASDAQ: NDRA ) +41% . Leap Therapeutics (NASDAQ: LPTX ) +31% . Stitch Fix (NASDAQ: SFIX ) +30% . Seelos Therapeutics (NASDAQ: SEEL ) +26% . Key Energy Services (NYSE: KEG ) +24% . Chaparral Energy (NYS...
Mersana Therapeutics (MRSN) Q4 2018 Earnings Conference Call March 08, 2019 08:00 AM ET Company Participants Sarah Carmody - IR and Corporate Communications Anna Protopapas - CEO Tim Lowinger - Chief Scientific Officer Dave Spellman - CFO Eva Jack - Chief Business Officer ...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; Expected to Fund the Company Through Important Clinical Milestones ...
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +130% . Puma Biotechnology (NYSE: PBYI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +30% . GlobalSCAPE (NYSEMKT: GSB ) +29% . Castlight Health (NYSE: CSLT ) +24% . Farfetch Limited (NYSE: FTCH ) +23% . Sequential Brands Group (NASD...
ImmunoGen (NASDAQ: IMGN ) -46% after mirvetuximab soravtansine flunks late-stage study. More news on: ImmunoGen, Inc., Mersana Therapeutics, Nutanix, Stocks on the move, Read more ...
Thinly traded micro cap Mersana Therapeutics (NASDAQ: MRSN ) slumps 29% premarket on light volume in response to its public offering of 21.25M shares of common stock at $4 per share. More news on: Mersana Therapeutics, Healthcare stocks news, Stocks on the move, Read more...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...